Ambrx Biopharma Inc. American Depositary Shares Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 23.50
(+139.06%)
Based on the Ambrx Biopharma Inc. American Depositary Shares stock forecast from 7 analysts, the average analyst target price for Ambrx Biopharma Inc. American Depositary Shares is USD 23.50 over the next 12 months. Ambrx Biopharma Inc. American Depositary Shares’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ambrx Biopharma Inc. American Depositary Shares is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Ambrx Biopharma Inc. American Depositary Shares’s stock price was USD 9.83. Ambrx Biopharma Inc. American Depositary Shares’s stock price has changed by +9.34% over the past week, -7.31% over the past month and +1,713.65% over the last year.
No recent analyst target price found for Ambrx Biopharma Inc. American Depositary Shares
No recent average analyst rating found for Ambrx Biopharma Inc. American Depositary Shares
Company Overview Ambrx Biopharma Inc. American Depositary Shares
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. Address: 10975 North Torrey Pines Road, La Jolla, CA, United States, 92037 Read Less
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize ...Read More
Frequently Asked Questions About Ambrx Biopharma Inc. American Depositary Shares (AMAM) Stock
Based on ratings from 7 analysts Ambrx Biopharma Inc. American Depositary Shares's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 8 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on AMAM's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for AMAM is USD 23.50 over the next 12 months. The maximum analyst target price is USD 33 while the minimum anlayst target price is USD 9.
AMAM stock's Price/Earning ratio is 23.40.
Our analysis grades AMAM stock's Price / Earning ratio at F. This means that AMAM stock's Price/Earning ratio is above 74% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AMAM may be a overvalued for its sector.
The last closing price of AMAM's stock was USD 9.83.
The most recent market capitalization for AMAM is USD 0.61B.
Based on targets from 7 analysts, the average taret price for AMAM is projected at USD 23.50 over the next 12 months.
This means that AMAM's stock price may go up by +139.06% over the next 12 months.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMAM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
